Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book

被引：6
|
作者：
Santos, Raul D. [1 ,2 ]
Rocha, Viviane Z. [1 ]
机构：
[1] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Lipid Clin, Av Dr Eneas C Aguiar 44, BR-05403900 Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷 / 02期
关键词：
EVOLOCUMAB;
D O I：
10.1093/eurheartj/ehac656
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'Inclisiran and cardiovascular events: a patient-level analysis of phase III trials, by K.K. Ray et al., https://doi.org/10. 1093/eurheartj/ehac594.
引用
收藏
页码：139 / 141
页数：3
相关论文
共 50 条
  • [41] Cholesterol reduction by immunization with a PCSK9 mimic
    Zhang, Baoshan
    Chuang, Gwo-Yu
    Biju, Andrea
    Biner, Daniel
    Cheng, Jiaxuan
    Wang, Yiran
    Bao, Saran
    Chao, Cara W.
    Lei, Haotian
    Liu, Tracy
    Nazzari, Alexandra F.
    Yang, Yongping
    Zhou, Tongqing
    Chen, Steven J.
    Chen, Xuejun
    Kong, Wing-Pui
    Ou, Li
    Parchment, Danealle K.
    Sarfo, Edward K.
    Sima, Haomin
    Todd, John -Paul
    Wang, Shuishu
    Woodward, Ruth A.
    Cheng, Cheng
    Rawi, Reda
    Mascola, John R.
    Kwong, Peter D.
    CELL REPORTS, 2024, 43 (06):
  • [42] PCSK9 antibody reduces LDL cholesterol
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2012, 11 : 11 - 11
  • [43] Cholesterol Management in the Era of PCSK9 Inhibitors
    Svatikova, Anna
    Kopecky, Stephen L.
    CURRENT CARDIOLOGY REPORTS, 2017, 19 (09)
  • [44] Cholesterol Management in the Era of PCSK9 Inhibitors
    Anna Svatikova
    Stephen L. Kopecky
    Current Cardiology Reports, 2017, 19
  • [45] Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?
    Ying, Qidi
    Ronca, Annalisa
    Chan, Dick C.
    Pang, Jing
    Favari, Elda
    Watts, Gerald F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52 (07)
  • [46] The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
    Lambert, Gilles
    Thedrez, Aurelie
    Croyal, Mikael
    Ramin-Mangata, Stephane
    Couret, David
    Diotel, Nicolas
    Nobecourt-Dupuy, Estelle
    Krempf, Michel
    LeBail, Jean Christophe
    Poirier, Bruno
    Blankenstein, Jorg
    Villard, Elise F.
    Guillot, Etienne
    CLINICAL SCIENCE, 2017, 131 (04) : 261 - 268
  • [47] The PCSK9 adventure - humanizing extreme LDL lowering
    Shapiro, Michael D.
    Fazio, Sergio
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (06) : 319 - 320
  • [48] The PCSK9 adventure — humanizing extreme LDL lowering
    Michael D. Shapiro
    Sergio Fazio
    Nature Reviews Cardiology, 2017, 14 : 319 - 320
  • [49] Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering
    Kirchhofer, Daniel
    Burdick, Daniel J.
    Skelton, Nicholas J.
    Zhang, Yingnan
    Ultsch, Mark
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2020, 48 (04) : 1323 - 1336
  • [50] Lipid Lowering Therapy and Circulating PCSK9 Concentration
    Nozue, Tsuyoshi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (09) : 895 - 907
12345